We observed that the combined treatment with 50 mg/kg of SMI-4a and 80 mg/kg of Akti-1/2 inhibited Abl-mediated tumor growth more potently than the treatment with either 50 mg/kg of SMI-4a or 80 mg/kg of Akti-1/2 alone (Figure 6A and 6B). This evidence concerns the gene ABL1 and neoplasm.